PFE Stock Recent News

Though there are plenty of dividend stocks on the market, they aren't all created equal. Consider that the average dividend yield for the S&P 500 (^GSPC -0.39%) is 1.3%, which is not particularly high.

Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains.

Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows increased control of its oncology pipeline and much higher financial rewards in the long run, and comes at a relatively low cost. The jury is still out on the PD-1/VEGF bispecific antibody class of drugs, but the data to date make this approach worth exploring, and perhaps even necessary.

Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.

Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.

PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.

CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news.

Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.

The trend is your friend is a well-known Wall Street catchphrase that often has proven to be correct.

If you see a stock that pays 6% in dividends, you might assume it's too risky -- but that's not always the case. In some situations, a yield can grow to such heights because investors have been dumping the stock.